News / Taiwan / economic_daily
Maywufa Group Marks 50th Anniversary with Strategic Expansion Across Three Subsidiaries
Health Technology · Biotechnology · economic_daily · 2026-10-25
1731
Maywufa Group is accelerating growth across its three core units—Maywufa, Vita Genomics, and Anke Bio—focusing on premium consumer goods, pharmaceutical profitability, and global smart medical device expansion.
What Happened
Group Strategic Vision: Celebrating its 50th anniversary, Maywufa Group is advancing growth strategies across its three subsidiaries: Maywufa, Vita Genomics, and Anke Bio. The group aims to drive future performance through consumer brand upgrades, clinical drug applications, and the international commercialization of smart medical devices.
Consumer Brand Growth: Maywufa is focusing on the premium hair care market by incorporating aesthetic medicine ingredients like exosomes and PDRN. The company is also leveraging AI and digital transformation to optimize production and logistics, maintaining its leadership in the domestic hair care market.
Pharmaceutical Turnaround: Vita Genomics is prioritizing a shift toward profitability, aiming to reach a break-even point within the next two to three years. The company is expanding the clinical use of its core drugs, including Vita Blood and Vita Pain, while pursuing international partnerships, such as a recent agreement with Germany's Aristo Pharma.
Smart Medical Expansion: Anke Bio is prioritizing the global commercialization of its AI-driven medical devices, with its sleep diagnostic tool already gaining insurance coverage at Stanford. The company is actively pursuing international distribution partnerships to scale its presence in the global AI medical imaging market.